Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Ask to Join - Clinical Trials

Fields marked with an * are required

First Name *

Last Name *

Email *

Phone

Country

Message *

Request Access To Clinical Trial Data

By submitting your inquiry, you are consenting to BeiGene and its Affiliates. processing your personal data as needed to provide the requested information. BeiGene and its Affiliates will only use the data you provide for this purpose and will delete the data after we have responded to you. In order to respond to your request, we may need to transfer your personal data to our affiliates and vendors in other countries, where the level of protection of personal data may not be the same as that of your Country. We will adopt adequate safeguards to protect your personal data. BeiGene and its Affiliates is committed to protecting your privacy and personal data. For information about how we use and protect your personal data, please see our Privacy Policy at https://www.beonemedicines.com/privacy-policy/.

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Beigene Study ID

BGB-3111-113

ClinicalTrials.gov ID

NCT04551963

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan